Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL-Reference-Cited by-同舟云学术

Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL

Published:2018-04-19 Issue:16 Volume:131 Page:1809-1819
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Vari Frank¹,Arpon David¹,Keane Colm¹²,Hertzberg Mark S.³,Talaulikar Dipti⁴⁵,Jain Sanjiv⁴,Cui Qingyan¹,Han Erica¹,Tobin Josh¹²,Bird Robert²,Cross Donna²,Hernandez Annette²,Gould Clare¹²,Birch Simone⁶,Gandhi Maher K.¹²^ORCID

Affiliation:

1. University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, QLD, Australia;

2. Department of Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australia;

3. Haematology, Prince of Wales Hospital, Sydney, NSW, Australia;

4. Canberra Hospital, Canberra, ACT, Australia;

5. Australian National University Medical School, Acton, ACT, Australia; and

6. Department of Pathology, Princess Alexandra Hospital, Brisbane, QLD, Australia

Abstract

Key Points Expansion of PD-1+ CD3−CD56hiCD16-ve NK cells and PD-L1+ monocytes/macrophages is more prominent in cHL than DLBCL. PD-1 blockade reverses the immune evasion mediated by the interaction of PD-1+ NK cells and PD-L1+ monocytes/macrophages.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/131/16/1809/1467877/blood796342.pdf

Reference61 articles.

1. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma;Ansell;N Engl J Med,2015

2. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial;Younes;Lancet Oncol,2016

3. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure;Armand;J Clin Oncol,2016

4. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma;Chen;J Clin Oncol,2017

5. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study;Lesokhin;J Clin Oncol,2016

Cited by 241 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Deciphering the Genetic Complexity of Classical Hodgkin Lymphoma: Insights and Effective Strategies;Current Genomics;2024-10

2. Natural killer cell-associated prognosis model characterizes immune landscape and treatment efficacy of diffuse large B cell lymphoma;Cytokine;2024-10

3. Intra‐tumoral and peripheral blood TIGIT and PD‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma;American Journal of Hematology;2024-08-17

4. Multiplex spatial analysis reveals increased CD137 expression and m-MDSC neighboring tumor cells in refractory classical Hodgkin Lymphoma;OncoImmunology;2024-08-10

5. Periodontitis is an immune-related adverse event associated with immune checkpoint inhibitors: A multi-center cohort study;Cancer Letters;2024-08